王欢

王 欢    副研究员

  中国北京市海淀区学院路38号js3845金沙线路系统生物医学研究所  100191

  电子邮箱：  huan_sharon_wang@pku.edu.cn     

王欢，js3845金沙线路系统生物医学研究所特聘副研究员，博士生导师。其博士后阶段在美国哈佛大学医学院及博士阶段在美国科罗拉多大学博尔德分校，分别从事系统药理学和心脏组织工程方面的研究。具体研究方向包括抗肿瘤药物引起心脏毒性的机制及潜在靶点，多组学数据的整合分析，微环境理化因子的调控机制。至今在Proceedings of the National Academy of Sciences of the United States of America, Cell Systems, Nature Reviews Cardiology, FASEB J等业界知名期刊上发表学术论文数篇。主持国自然基金一项。目前担任中国病生理学会系统生物医学青年专委会委员。

 

教育及工作经历

2018.7 ~ 至今js3845金沙线路系统生物医学研究所副研究员

2014.9 ~ 2018.6 哈佛医学院，系统生物学系，博士后（导师：Peter K. Sorger）

2013.5 ~ 2014.9 科罗拉多大学波尔德分校，化学与生物工程系，博士后(导师：Kristi S. Anseth)

2006.9 ~ 2013.5 科罗拉多大学波尔德分校，分子，细胞与发育生物学系，博士（导师: Leslie A. Leinwand and Kristi S. Anseth）

2004.9 ~ 2005.6 香港中文大学, 生物系, 交换学生

2002.9 ~ 2006.7 浙江大学，生物技术系，学士

 

Education and working experience

2018.7 ~ present Peking University Health Science Center, Institute of Systems Biomedicine, Assistant professor

2014.9 ~ 2018.6 Harvard Medical School，Department of Systems Biology，Postdoctoral fellow (Adviser: Peter K. Sorger)

2013.5 ~ 2014.9 University of Colorado at Boulder, Chemical and Biological Engineering，Postdoctoral fellow (Adviser: Kristi S. Anseth)

2006.9 ~ 2013.5 University of Colorado at Boulder, Department of Molecular, Cellular and Developmental Biology, PhD. (Advisers: Leslie Leinwand and Kristi Anseth)

2004.9 ~ 2005.6 Chinese University of Hong Kong, Exchange student

2002.9 ~ 2006.7 Zhejiang University, Department of Biotechnology, B.S. in Biotechnology (graduated with summa cum laude)              

 

研究方向：

抗肿瘤药物所引起的心脏毒性  多组学数据的整合分析  心肌组织再生工程  

 

Research directions:

1. Drug-induced cardiotoxicity (We will initially focus on cancer drugs, such as tyrosine kinase inhibitors, immune checkpoint inhibitors, etc.)

2. Integrative multi-omics (transcriptomics, proteomics and metabolomics) data analysis

3. Cardiac muscle tissue engineering

 

Representative publications （代表性论文）:

1. Wang H, Sheehan RP, Palmer AC, Everley RA, Boswell SA, Ron-Harel N, Ringel AE, Holton KM, Jacobson CA, Alison RE, Maliszewski L, Haigis MC, Sorger PK. Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming. Cell Syst 8, 412-426.e7 (2019).

2. Wang H, Tibbitt MW, Langer SJ, Leinwand LA and Anseth KS. Hydrogels preserve native phenotypes of valvular fibroblasts through an elasticity-regulated PI3K/AKT pathway. Proceedings of the National Academy of Sciences USA, 110 (48): 19336-19341 (2013).

3. Wang H, Leinwand LA and Anseth KS. Cardiac valve cells and their microenvironment—insights from in vitro studies, Nature Reviews Cardiology, 11(12):715-727 (2014).

4. Wang H, Leinwand LA and Anseth KS. Roles of transforming growth factor-β1 and OB-cadherin in porcine cardiac valve myofibroblast differentiation, The FASEB Journal, 28(10):4551-4562 (2014).

5. Wang H, Haeger SM, Kloxin AK, Leinwand LA and Anseth KS. Redirecting valvular myofibroblasts into dormant fibroblasts through light-mediated reduction in substrate modulus. PLoS ONE, 7(7):e39969 (2012).

6. Wang H, Sridhar B, Leinwand LA, Anseth KS. Characterization of cell subpopulations expressing progenitor cell markers in porcine cardiac valves. PLoS ONE, 8(7): e69667. https://doi.org/10.1371/journal.pone.0069667(2013).

 

Contact:

Institute of Systems Biomedicine

Peking University School of Medical Sciences.

Xueyuan Road 38,

Haidian District, Beijing 100191

Email：huan_sharon_wang@pku.edu.cn